Cargando…

Growth-Inhibiting Activity of Resveratrol Imine Analogs on Tumor Cells In Vitro

Although resveratrol exerts manifold antitumorigenic effects in vitro, its efficacy against malignancies in vivo seems limited. This has been increasingly recognized in recent years and has prompted scientists to search for structurally related compounds with more promising anticarcinogenic and/or p...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shan, Willenberg, Ina, Krohn, Michael, Hecker, Tanja, Meckelmann, Sven, Li, Chang, Pan, Yuanjiang, Schebb, Nils Helge, Steinberg, Pablo, Empl, Michael Telamon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5256997/
https://www.ncbi.nlm.nih.gov/pubmed/28114318
http://dx.doi.org/10.1371/journal.pone.0170502
_version_ 1782498792112652288
author Wang, Shan
Willenberg, Ina
Krohn, Michael
Hecker, Tanja
Meckelmann, Sven
Li, Chang
Pan, Yuanjiang
Schebb, Nils Helge
Steinberg, Pablo
Empl, Michael Telamon
author_facet Wang, Shan
Willenberg, Ina
Krohn, Michael
Hecker, Tanja
Meckelmann, Sven
Li, Chang
Pan, Yuanjiang
Schebb, Nils Helge
Steinberg, Pablo
Empl, Michael Telamon
author_sort Wang, Shan
collection PubMed
description Although resveratrol exerts manifold antitumorigenic effects in vitro, its efficacy against malignancies in vivo seems limited. This has been increasingly recognized in recent years and has prompted scientists to search for structurally related compounds with more promising anticarcinogenic and/or pharmacokinetic properties. A class of structurally modified resveratrol derivatives, so-called resveratrol imine analogs (IRA’s), might meet these requirements. Therefore, the biological activity of five of these compounds was examined and compared to that of resveratrol. Firstly, the antiproliferative potency of all five IRA’s was investigated using the p53 wildtype-carrying colorectal carcinoma cell line HCT-116(wt). Then, using the former and a panel of various other tumor cell lines (including the p53 knockout variant HCT-116(p53-/-)), the growth-inhibiting and cell cycle-disturbing effects of the most potent IRA (IRA 5, 2-[[(2-hydroxyphenyl)methylene]amino]-phenol) were studied as was its influence on cyclooxygenase-2 expression and activity. Finally, rat liver microsomes were used to determine the metabolic stability of that compound. IRA 5 was clearly the most potent compound in HCT-116(wt) cells, with an unusually high IC(50)-value of 0.6 μM. However, in the other five cell lines used, the antiproliferative activity was mostly similar to resveratrol and the effects on the cell cycle were heterogeneous. Although all cell lines were affected by treatment with IRA 5, cells expressing functional p53 seemed to react more sensitively, suggesting that this protein plays a modulating role in the induction of IRA 5-mediated biological effects. Lastly, IRA 5 led to contradictory effects on cyclooxygenase-2 expression and activity and was less glucuronidated than resveratrol. As IRA 5 is approximately 50 times more toxic towards HCT-116(wt) cells, exerts different effects on the cyclooxygenase-2 and is metabolized to a lesser extent, it shows certain advantages over resveratrol and could therefore serve as basis for additional chemical modifications, potentially yielding compounds with more favorable biological and pharmacokinetic features.
format Online
Article
Text
id pubmed-5256997
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-52569972017-02-06 Growth-Inhibiting Activity of Resveratrol Imine Analogs on Tumor Cells In Vitro Wang, Shan Willenberg, Ina Krohn, Michael Hecker, Tanja Meckelmann, Sven Li, Chang Pan, Yuanjiang Schebb, Nils Helge Steinberg, Pablo Empl, Michael Telamon PLoS One Research Article Although resveratrol exerts manifold antitumorigenic effects in vitro, its efficacy against malignancies in vivo seems limited. This has been increasingly recognized in recent years and has prompted scientists to search for structurally related compounds with more promising anticarcinogenic and/or pharmacokinetic properties. A class of structurally modified resveratrol derivatives, so-called resveratrol imine analogs (IRA’s), might meet these requirements. Therefore, the biological activity of five of these compounds was examined and compared to that of resveratrol. Firstly, the antiproliferative potency of all five IRA’s was investigated using the p53 wildtype-carrying colorectal carcinoma cell line HCT-116(wt). Then, using the former and a panel of various other tumor cell lines (including the p53 knockout variant HCT-116(p53-/-)), the growth-inhibiting and cell cycle-disturbing effects of the most potent IRA (IRA 5, 2-[[(2-hydroxyphenyl)methylene]amino]-phenol) were studied as was its influence on cyclooxygenase-2 expression and activity. Finally, rat liver microsomes were used to determine the metabolic stability of that compound. IRA 5 was clearly the most potent compound in HCT-116(wt) cells, with an unusually high IC(50)-value of 0.6 μM. However, in the other five cell lines used, the antiproliferative activity was mostly similar to resveratrol and the effects on the cell cycle were heterogeneous. Although all cell lines were affected by treatment with IRA 5, cells expressing functional p53 seemed to react more sensitively, suggesting that this protein plays a modulating role in the induction of IRA 5-mediated biological effects. Lastly, IRA 5 led to contradictory effects on cyclooxygenase-2 expression and activity and was less glucuronidated than resveratrol. As IRA 5 is approximately 50 times more toxic towards HCT-116(wt) cells, exerts different effects on the cyclooxygenase-2 and is metabolized to a lesser extent, it shows certain advantages over resveratrol and could therefore serve as basis for additional chemical modifications, potentially yielding compounds with more favorable biological and pharmacokinetic features. Public Library of Science 2017-01-23 /pmc/articles/PMC5256997/ /pubmed/28114318 http://dx.doi.org/10.1371/journal.pone.0170502 Text en © 2017 Wang et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Wang, Shan
Willenberg, Ina
Krohn, Michael
Hecker, Tanja
Meckelmann, Sven
Li, Chang
Pan, Yuanjiang
Schebb, Nils Helge
Steinberg, Pablo
Empl, Michael Telamon
Growth-Inhibiting Activity of Resveratrol Imine Analogs on Tumor Cells In Vitro
title Growth-Inhibiting Activity of Resveratrol Imine Analogs on Tumor Cells In Vitro
title_full Growth-Inhibiting Activity of Resveratrol Imine Analogs on Tumor Cells In Vitro
title_fullStr Growth-Inhibiting Activity of Resveratrol Imine Analogs on Tumor Cells In Vitro
title_full_unstemmed Growth-Inhibiting Activity of Resveratrol Imine Analogs on Tumor Cells In Vitro
title_short Growth-Inhibiting Activity of Resveratrol Imine Analogs on Tumor Cells In Vitro
title_sort growth-inhibiting activity of resveratrol imine analogs on tumor cells in vitro
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5256997/
https://www.ncbi.nlm.nih.gov/pubmed/28114318
http://dx.doi.org/10.1371/journal.pone.0170502
work_keys_str_mv AT wangshan growthinhibitingactivityofresveratrolimineanalogsontumorcellsinvitro
AT willenbergina growthinhibitingactivityofresveratrolimineanalogsontumorcellsinvitro
AT krohnmichael growthinhibitingactivityofresveratrolimineanalogsontumorcellsinvitro
AT heckertanja growthinhibitingactivityofresveratrolimineanalogsontumorcellsinvitro
AT meckelmannsven growthinhibitingactivityofresveratrolimineanalogsontumorcellsinvitro
AT lichang growthinhibitingactivityofresveratrolimineanalogsontumorcellsinvitro
AT panyuanjiang growthinhibitingactivityofresveratrolimineanalogsontumorcellsinvitro
AT schebbnilshelge growthinhibitingactivityofresveratrolimineanalogsontumorcellsinvitro
AT steinbergpablo growthinhibitingactivityofresveratrolimineanalogsontumorcellsinvitro
AT emplmichaeltelamon growthinhibitingactivityofresveratrolimineanalogsontumorcellsinvitro